Skip Navigation


Journal of the National Cancer Institute Advance Access originally published online on June 12, 2007
JNCI Journal of the National Cancer Institute 2007 99(12):908-909; doi:10.1093/jnci/djm013
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
99/12/908    most recent
djm013v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Wacholder, S.
Right arrow Articles by Hartge, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wacholder, S.
Right arrow Articles by Hartge, P.
Related Collections
Right arrowRelated Articles in JNCI
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2007. Published by Oxford University Press.

EDITORIALS

Studies of Genes and Cancer Survival: Pieces of the Puzzle

Sholom Wacholder, Jennifer K. Loukissas, Patricia Hartge

Affiliation of authors: Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD

Correspondence to: Sholom Wacholder, PhD, Biostatistics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, EPN 8046, Bethesda, MD 20892-7244 (e-mail: wacholds@mail.nih.gov).

The first 10% of the full text of this article appears below.

Men who carry BRCA2 mutations are known to have an increased risk of being diagnosed with prostate cancer (1,2). In this issue of the Journal, Tryggvadóttir et al. (3) report that 29 prostate cancer patients who carried the Icelandic founder mutation 999del5 in BRCA2 had unusually advanced disease at diagnosis and poor survival. Using registry data from the entire Icelandic population, the investigators compared stage and grade at diagnosis and length of survival between carriers and noncarriers. This work may clarify when and how BRCA2 mutations alter carcinogenesis. . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related Articles in JNCI

IN THIS ISSUE
J Natl Cancer Inst 2007 99: 905. [Extract] [Full Text] [PDF]

Press Release: BRCA2 Carriers At Increased Risk for Deadly Form of Prostate Cancer
Liz Savage
J Natl Cancer Inst 2007 99: 905. [Extract] [Full Text]